I turned 50 during the pandemic and, like most people, I put off all nonessential health care, including my shingles vaccine. Big mistake. When the telltale red bumps of shingles cropped up on my face ...

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...

Dr. Matthew Simmons, UPMC Western Maryland vice president of medical staff affairs, said vaccines provide the "single most powerful intervention" that have saved lives. He recently discussed the ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Megyn Kelly is joined by Turning Point USA's Charlie Kirk, host of The Charlie Kirk Show, to talk about RFK Jr. getting ...

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...

Vaccination with GSK's recombinant shingles vaccine, Shingrix, could delay the onset of dementia, according to researchers in the UK. A study published in Nature Medicine suggests that people ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...